Navigation Links
Generex Announces Patent Award for its Core Vaccine Technologies in Japan
Date:2/1/2012

WORCESTER, Mass. and TORONTO, Feb. 1, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been awarded a Japanese Patent centering on its Ii-Key technology for the development of immunotherapeutic vaccines.  A number of products developed with this technology are currently in clinical development.  The patent helps to secure the novel Antigen Express vaccine technology platform in the international community.  International counterparts have been granted in Australia, China, and the United States.  The European counterpart has been allowed, and the Canadian application is pending.

(Photo:  http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

About AE37 and Ii-Key Hybrid Platform Technology

Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs.  The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells.  Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.

The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37).  This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches.  AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Announces $3.0 Million Capital Investment
10. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
11. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources ... Brazil and Mexico ... uptake of several newly approved agents, the anticipated ... indication and the launch of emerging biologics will ... In particular, the emerging IL-5 inhibitors will introduce ...
(Date:8/21/2014)... VIEW, Calif. , Aug. 21, 2014 /PRNewswire/ ... properties and behaviors based on external stimuli such ... poised to have a disruptive effect in multiple ... revolutionize the business landscape by printing objects ranging ... aerospace and automotive sectors. Logo - ...
(Date:8/21/2014)... SoundConnect , a unified ... one of the nation’s Fastest Growing Private Companies ... 2nd consecutive year. Inc. magazine today ranked SoundConnect ... an exclusive ranking of the nation's fastest-growing private ... at the most important segment of the economy—America’s ...
(Date:8/20/2014)... often have it that American Indians largely were wiped ... influenza and tuberculosis brought to the New World by ... 20 million people lived in the Americas shortly before ... killed by European diseases., But new research led by ... Johannes Krause of the University of Tubingen in Germany ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
... Toronto Stock Exchange Symbol: MS , ... EDMONTON, AB , ... today announced its updated corporate strategy. The Company,s new strategy ... industry, whereby BioMS will directly invest in and advise companies ...
... , May 3 The Global Alliance for ... the 2010 BIO International Convention that they have entered into ... clinical use of drugs against tuberculosis (TB), including drug resistant ... are resistant to at least one of today,s standard first-line ...
... , WALTHAM, Mass. , May 3 Interleukin ... Lewis H. Bender will moderate and co-present a panel ... Development: How to Improve Efficacy and Commercial Success" at the BIO ... Chicago, IL.  The panel discussion will be held Wednesday, ...
Cached Biology Technology:BioMS updates corporate strategy and adds leading healthcare investment banker 2BioMS updates corporate strategy and adds leading healthcare investment banker 3TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 2TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 3TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 4Interleukin Genetics to Present at Upcoming Biotech Industry Meetings 2
(Date:8/21/2014)... team of researchers at Louisiana Tech University ... affordable, consumer-grade 3D printers and materials to ... antibacterial and chemotherapeutic compounds for targeted drug ... students and research faculty from Louisiana Tech,s ... to create filament extruders that can make ...
(Date:8/21/2014)... the pancreas digesting itself resulting in severe abdominal pain, ... around 20,000 patients are diagnosed with the disease resulting ... treatment is restricted to intravenous fluid and nutritional support. ... Life Sciences, who led the research, said "The major ... stones and excessive alcohol intake combined with a high ...
(Date:8/20/2014)... (HCI) at the University of Utah have identified and ... the unregulated enzyme driving the blood cancer chronic myeloid ... 6,000 new cases of CML will be diagnosed in ... inhibitors (TKIs), target BCR-ABL and are effective at controlling ... it in a way that allows patients to get ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... an iron storage molecule in the cell can serve ... gene therapy may use a technique in which non-invasive ... molecule. The results of this research, conducted by Prof. ... were published in the research journal Neoplasia. , Neeman, ...
... at Washington University in St. Louis has shown that ... sexual organs, and actually choose them for mating. That ... called a gonopodium. These fish out-compete the larger-endowed males ... burst speed than the males with larger genitalia, who ...
... show that stem cell therapy can be used effectively to ... two months, stem cells harvested from another pig's bone marrow ... and repaired damaged heart muscle by 50 percent to 75 ... the 2004 Scientific Sessions of the American Heart Association, are ...
Cached Biology News:Novel live reporting system to track cells 2IMF Launches World’s First DNA Database for Myeloma Patients 2IMF Launches World’s First DNA Database for Myeloma Patients 3IMF Launches World’s First DNA Database for Myeloma Patients 4Stem cell therapy successfully treats heart attack in animals 2
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
...
... HDAC4 - ChIP Grade HDAC4 is ... histone deacetylases, which consists of 1084 amino ... similar to the deacetylase domain of yeast ... the nucleus and cytoplasm in a process ...
...
Biology Products: